Physician profile
Brian S Lee
NPI 1295911287
$3,072.63
in general payments reported to CMS, 2019-2025
30 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $143 · 2021: $695 · 2022: $723 · 2023: $405 · 2024: $419 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.18 | 2021-2024 | |
| Novo Nordisk INC | $473.40 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $252.97 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.26 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $225.22 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $222.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $193.27 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $102.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $98.94 | 2019-2022 | |
| Pfizer INC. | $97.51 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $81.24 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $81.18 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $51.47 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $46.05 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.92 | 2019-2020 | |
| Exact Sciences Corporation | $32.43 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.17 | 2025 | Caplyta |
| Seqirus USA INC | $19.32 | 2025 | Fluad, Flucelvax |
| Sanofi-Aventis U.S. LLC | $16.50 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.33 | 2020 | |
| Gilead Sciences, INC. | $15.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.70 | 2021 | |
| Currax Pharmaceuticals LLC | $14.06 | 2021 | |
| Dexcom, INC. | $13.33 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $13.12 | 2021 | |
| Eisai INC. | $12.59 | 2021 | |
| Medtronic, INC. | $12.31 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.14 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.